Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06869057 · ClinicalTrials.gov registry record · NA
Re-Engineered Discharge for Diabetes Care Transitions
A NA study, sponsored by University of Massachusetts, Worcester.
- Recruiting
- Registry status
- NA
- Development phase
- 412
- Enrollment target
NCT06869057: Recruiting NA study, sponsored by University of Massachusetts, Worcester.
NCT06869057 is a NA study that is actively recruiting participants, run by University of Massachusetts, Worcester. The registered enrollment target is 412 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06869057, a NA study, is actively recruiting participants, sponsored by University of Massachusetts, Worcester.
- RECRUITING
- Registry status
- NA
- Development phase
- 412 participants
- Enrollment target
Study Summary
The goal of this project is to test a novel bedside SDOH screening intervention coupled with post-discharge navigation for hospitalized patients with a diabetes diagnosis to reduce unmet social needs, compared to usual care.
Primary Outcome
The primary outcome is a composite measure on all types of hospital service use (emergency department, observation, or hospital readmissions), pre-specified as time-to-hospital reutilization, at 90-days post-hospital discharge. Source of the data are UMMH electronic health records and participant self-report.
Interventions
- OTHER Treatment as Usual (TAU)
- BEHAVIORAL REDDCAT2 Post-Discharge Navigation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 412 participants |
| Start Date | 2026-06-08 |
| Est. Completion | 2029-05-30 |
| Phase | NA |
What NCT06869057 shows while recruiting
NCT06869057 is an interventional study that assigns participants to a tested intervention. The registered 412 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which Treatment as Usual (TAU) is the first listed.
NCT06869057 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06869057 about?
NCT06869057 is a clinical study titled "Re-Engineered Discharge for Diabetes Care Transitions". The goal of this project is to test a novel bedside SDOH screening intervention coupled with post-discharge navigation for hospitalized patients with a diabetes diagnosis to reduce unmet social needs, compared to usual care.
What is the current status of trial NCT06869057?
This trial is currently recruiting. It is a NA study. The enrollment target is 412 participants. The study started on 2026-06-08. Estimated completion is 2029-05-30.
What interventions are being tested in trial NCT06869057?
The interventions under investigation include: Treatment as Usual (TAU) (OTHER), REDDCAT2 Post-Discharge Navigation (BEHAVIORAL).
Who is sponsoring clinical trial NCT06869057?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06869057's enrollment target sits among peer trials
412 241st of 2000 higher than 1,759 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05993689 · 412 participants · NA
Building TrUst and UNiting Teams Through DouLa partnErship - BUNDLE
- NCT06699212 · 412 participants · Phase 3
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- NCT03592472 · 413 participants · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- NCT06697197 · 413 participants · Phase 1
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI